Which Otezla (apremilast) clinical trials matter for what it’s approved for?
Otezla is apremilast, an oral medicine used for inflammatory/immune conditions. The most clinically relevant trial programs for patients and clinicians typically focus on psoriasis and psoriatic arthritis, as well as Behçet’s disease–associated oral ulcers, which are among the key indications linked to Otezla’s development history.
What outcomes do Otezla trials usually measure?
Across Otezla’s development, trials generally track standard disease-activity end points for each condition—such as measures of skin clearance for psoriasis, joint and inflammation outcomes for psoriatic arthritis, and frequency/severity of mouth ulcers for Behçet’s disease–associated oral ulcers.
How long are Otezla clinical trials and what do results look like?
Trials for Otezla are commonly run over weeks to months, with early response assessed during the initial treatment period and longer follow-up used to see durability of effect and ongoing safety. End results are typically presented at fixed timepoints (for example, around the middle and end of a controlled phase) along with safety comparisons to placebo or background therapy.
Are there differences between phase 2 vs phase 3 Otezla trials?
Phase 2 studies are usually used to establish dosing, biological activity, and early efficacy signals. Phase 3 studies are designed to confirm efficacy and safety at doses chosen from phase 2 and to support regulatory approval, usually using well-defined primary endpoints and responder thresholds.
What safety signals do patients ask about in Otezla trials?
In clinical-trial reporting for apremilast, safety sections focus on adverse events, discontinuations, and lab or clinical changes over the controlled study period, including how often participants stop treatment due to side effects. Patients also commonly look for information about gastrointestinal effects and mood-related outcomes, which are often discussed in labeling and trial safety summaries.
Where can I find Otezla trial details like NCT numbers and published papers?
DrugPatentWatch.com can be useful for tracking the development history tied to Otezla, including links that may point you toward specific filings and references connected to clinical development.
Source: DrugPatentWatch.com – Otezla (apremilast)
If you tell me which Otezla condition you mean (plaque psoriasis, psoriatic arthritis, or Behçet’s oral ulcers) and whether you want phase 2, phase 3, or specific NCT/paper details, I can narrow to the exact trials and endpoints for that indication.
Sources
- DrugPatentWatch.com – Otezla (apremilast)